Policy & Regulation
AstraZeneca secures US approval for Imfinzi–BCG regimen in high‑risk bladder cancer
...
Innovent Biologics and Pfizer agree global collaboration to develop innovative oncology medicines
29 May 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HK:01801) and US-based pharmaceutical company Pfizer Inc (NYSE:PFE), have announced on Thursday that they have entered into a st...
FDA approves TREMFYA label expansion
29 May 2026 - Pharmaceutical company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Appli...
Phanes Therapeutics reports updated Phase 2 results for spevatamig (PT886) in combination with chemotherapy
29 May 2026 - Clinical stage biotech company Phanes Therapeutics Inc announced on Thursday the release of updated positive Phase 2 results of spevatamig (PT886) in combination with chemotherapy in fro...
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
28 May 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) on Thursday reported positive phase III results for bepirovirsen, its investigational treatment for chronic hepatitis B, with poole...
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
28 May 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that the US Food and Drug Administration (FDA) has granted priority review for its new drug ...